Antibody cuts migraine frequency in difficult-to-treat cases

A large international study shows fremanezumab is an effective prevention therapy

The human monoclonal antibody, fremanezumab, can rapidly halve migraine frequency in some difficult-to-treat patients, an international trial shows.